Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2025)
Historic Gross Margin for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Q3 2025 value amounting to 88.87%.
- Aurinia Pharmaceuticals' Gross Margin fell 22300.0% to 88.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.93%, marking a year-over-year increase of 16800.0%. This contributed to the annual value of 87.99% for FY2024, which is 39500.0% down from last year.
- As of Q3 2025, Aurinia Pharmaceuticals' Gross Margin stood at 88.87%, which was down 22300.0% from 89.84% recorded in Q2 2025.
- In the past 5 years, Aurinia Pharmaceuticals' Gross Margin registered a high of 98.82% during Q1 2022, and its lowest value of 84.42% during Q2 2024.
- Its 5-year average for Gross Margin is 92.46%, with a median of 94.33% in 2022.
- In the last 5 years, Aurinia Pharmaceuticals' Gross Margin crashed by -141900bps in 2024 and then soared by 54100bps in 2025.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Gross Margin stood at 97.94% in 2021, then fell by -3bps to 95.21% in 2022, then decreased by -8bps to 88.04% in 2023, then increased by 3bps to 90.73% in 2024, then dropped by -2bps to 88.87% in 2025.
- Its Gross Margin stands at 88.87% for Q3 2025, versus 89.84% for Q2 2025 and 86.27% for Q1 2025.